Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens
- PMID: 12082397
Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens
Abstract
Objectives: Immunity to the human immunodeficiency virus type-1 (HIV-1) G/P-92 fusion protein consisting of highly immunogenic regions of Gag (p17 and p24) and Pol (p51) expressed in recombinant vaccinia virus (vG/P-92) was compared with responses to the entire viral Gag-Pol precursor protein (vVK1).
Study design/methods: We analyzed the level of Gag and Pol protein expression in vG/P-92-infected cells as well as the ability of the G/P-92 fusion protein to form virus-like particles (VLP) in infected cultures. The efficacy of vG/P-92 and vVK1 vaccines was evaluated in a murine model by measuring T helper (Th), cytotoxic T lymphocyte (CTL), and antibody responses to Gag and Pol antigens.
Results: The deletion of a frameshift site resulted in an increased level of Pol in cells expressing the G/P-92 fusion protein. Particles budding from the plasma membrane were detected in both vG/P-92- and vVK1-infected cells, but the release of VLP was less efficient from cells expressing the G/P-92 fusion protein than the entire gag-pol gene product. Immunization with vG/P-92 vector elicited a higher level of cellular and humoral responses to both Gag and Pol antigens than the vVK1 vaccine.
Conclusions: The enhanced immunogenicity of the G/P-92 fusion protein compared with the entire viral gag-pol gene product might be related to a higher intracellular level of Pol and Gag expression due to the deletion of a frameshift site and less efficient transport of VLP from vG/P-92-infected cells, respectively.
Similar articles
-
Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.Biol Chem. 1999 Mar;380(3):353-64. doi: 10.1515/BC.1999.047. Biol Chem. 1999. PMID: 10223338
-
Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.AIDS. 1993 Oct;7(10):1315-23. AIDS. 1993. PMID: 8267904
-
Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.Virology. 2005 Feb 20;332(2):467-79. doi: 10.1016/j.virol.2004.09.043. Virology. 2005. PMID: 15680412
-
Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine.Dev Biol Stand. 1994;82:159-62. Dev Biol Stand. 1994. PMID: 7958470 Review.
-
Molecular approaches to AIDS vaccine development using baculovirus expression vectors.Methods Mol Biol. 1995;39:295-315. doi: 10.1385/0-89603-272-8:295. Methods Mol Biol. 1995. PMID: 7542523 Review. No abstract available.
Cited by
-
The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.Protein Sci. 2008 Jun;17(6):1077-85. doi: 10.1110/ps.083443908. Epub 2008 Apr 14. Protein Sci. 2008. PMID: 18411420 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources